This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robinson, L. A. Articles by Stevens, C. W. Search for Related Content PubMed PubMed Citation Articles by Robinson, L. A. Articles by Stevens, C. W.

Treatment of Non-small Cell Lung Cancer-Stage IIIA^*

ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)

^* From the Department of Interdisciplinary Oncology (Dr. Robinson and Dr. Stevens), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Barbara Ann Karmanos Cancer Institute and Cancer Foundation (Dr. Ruckdeschel), Detroit, MI; and Department of Radiation Oncology (Dr. Wagner), Milton S. Hershey Medical Center, Hershey, PA.

Correspondence to: Lary A. Robinson, MD, Division of Cardiovascular and Thoracic Surgery, Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612-9497; e-mail: robinson{at}moffitt.usf.edu

Study objectives: Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. This review explores the published clinical trials to make treatment recommendations in this controversial subset of lung cancer.

Design, setting, and participants: Systematic searches were made of MEDLINE, HealthStar, and Cochrane Library databases up to May 2006, focusing primarily on randomized trials, with inclusion of selected metaanalyses, practice guidelines, and reviews. Study designs and results are summarized in evidence tables.

Measurement and results: The evidence derived from the literature now appears to support routine adjuvant chemotherapy after complete resection of stage IIIA lung cancer encountered unexpectedly at surgery. However, using neoadjuvant therapy followed by surgery for known stage IIIA lung cancer as a routine therapeutic option is not supported by current published randomized trials. Combination chemoradiotherapy, especially delivered concurrently, is still the preferred treatment for prospectively recognized stage IIIA lung cancer with all degrees of mediastinal lymph node involvement. Current and future trials may modify these recommendations.

Conclusions: Multimodality therapy of some type appears to be preferable in all subsets of stage IIIA patients. However, because of the relative lack of consistent randomized trial data in this subset, the following evidence-based treatment guidelines lack compelling evidence in most scenarios.

Key Words: adjuvant chemotherapy • adjuvant radiotherapy • chemotherapy • guidelines • lung carcinoma • neoadjuvant therapy • non-small cell lung cancer • pulmonary surgical procedures • radiation therapy

This article has been cited by other articles:

				D. Rice, S. Swisher, K. Pisters, F. Fossella, R. Herbst, W. Hofstetter, M. Kies, R. Komaki, S. Lippman, R. Mehran, et al. Comment on "Treatment of Non-small Cell Lung Cancer Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)" Chest, December 1, 2008; 134(6): 1349 - 1349. [Full Text] [PDF]

				L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr., and C. W. Stevens Response Chest, December 1, 2008; 134(6): 1350 - 1350. [Full Text] [PDF]